NHWK

NIGHTHAWK RADIOLOGY HOLDINGS INC
NHWK

Delisted

NHWK was delisted on the 22nd of December, 2010.

Back to rankings

Healthcare Medical Care Facilities

Financial journalist opinion

Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University

DURHAM, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it has been awarded a contract in excess of $1 million with an NIH-funded researcher at a major university.

Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University

Scorpius Holdings Accepted as a Member of the US Government's BioMaP-Consortium

Provides Access to Growth Funding and Enhanced Access to Federal Projects Provides Access to Growth Funding and Enhanced Access to Federal Projects

Scorpius Holdings Accepted as a Member of the US Government's BioMaP-Consortium

Scorpius Holdings, Inc. Announces Closing of Public Offering

DURHAM, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the closing of its previously announced public offering of 10,000,000 shares of its common stock at a public offering price of $0.15 per share, for gross proceeds of $1,500,000, before deducting underwriting discounts and offering expenses.

Scorpius Holdings, Inc. Announces Closing of Public Offering

Scorpius Holdings, Inc. Announces Pricing of Public Offering

DURHAM, N.C., March 08, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $0.15 per share, for aggregate gross proceeds of $1,500,000, before deducting underwriting discounts, commissions and offering expenses. All of the shares of common stock were offered by the Company. The offering is expected to close on March 12, 2024, subject to satisfaction of customary closing conditions.

Scorpius Holdings, Inc. Announces Pricing of Public Offering

Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock

DURHAM, N.C., March 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced that it intends to offer to sell shares of its common stock to the public in an underwritten public offering. All of the shares of common stock are to be sold by the Company.

Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock

Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023

Estimates Sequential Reduction in the Fourth Quarter of 2023 Operating Loss by Over $3.3 Million or Approximately 30% Compared to the Third Quarter of 2023

Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023

NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today

DURHAM, N.C., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences / Scorpius Holdings, Inc. (NYSE American: NHWK ; SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it had completed its name change from NightHawk Biosciences, Inc. to Scorpius Holdings, Inc., to better reflect the Company's successful shift into a pure-play, large molecule biomanufacturing CDMO. In connection with the name change, the Company's ticker will change to “SCPX” effective today, February 6, 2024. The name and symbol changes do not affect the Company's share structure or the rights of the Company's shareholders, and no further action will be required by existing shareholders.

NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today

NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note

DURHAM, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced it has sold additional none-core IP. Additionally, the Company received proceeds of $2.25 million from a note issued pursuant to the terms of the previously announced divestiture of non-core assets ( the “Note”). The Note bears interest at an annual rate of 1% and, subject to stockholder approval, would be convertible into shares of NightHawk's common stock at $0.39281 per share, an 8% premium to the closing price of the Company's common stock on January 29, 2024.

NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note

NightHawk's Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program

Project to benefit from Scorpius' comprehensive services in process development, bioanalysis, and cGMP manufacturing Project to benefit from Scorpius' comprehensive services in process development, bioanalysis, and cGMP manufacturing

NightHawk's Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program

NightHawk's Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client

Project reflects Scorpius' versatility through its multi-functional biologics facility and expertise in microbial fermentation Project reflects Scorpius' versatility through its multi-functional biologics facility and expertise in microbial fermentation

NightHawk's Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client

See News Rankings

Charts implemented using Lightweight Charts™